<DOC>
	<DOCNO>NCT02390700</DOCNO>
	<brief_summary>The purpose study evaluate incidence management infusion reaction Golimumab intravenous infusion .</brief_summary>
	<brief_title>Observational Study Golimumab Intravenous Infusion</brief_title>
	<detailed_description>This prospective , observational , non-interventional ( treatment give course study ) multi-center ( one hospital medical school team work medical research study ) , study enroll participant rheumatoid arthritis ( RA ) Canada . Only data available source documentation collect . The participation study impact standard care participant benefit otherwise entitle . All aspect treatment decision clinical management participant accordance clinical practice discretion health care provider . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Participants must confirm diagnosis rheumatoid arthritis Participants must provide write consent data collection signing informed consent form indicate he/she understand purpose procedure data collection willing participate study Participants golimumabnaive ( never use golimumab SC IV formulation ) Participants prescribe golimumab intravenous appropriate physician per Canadian Product Monograph Exclusion criterion : Participant treat golimumab past Participant diagnose psoriatic arthritis ankylose spondylitis Participant receive investigational drug ( include investigational vaccine ) use invasive investigational medical device within 30 day start study first data collection time point Participant currently enrol interventional study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Observational</keyword>
	<keyword>Golimumab</keyword>
	<keyword>SIMPONI</keyword>
	<keyword>Intravenous Infusion</keyword>
</DOC>